Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (23253)	7/15/1998 7:47:00 PM
From: Henry Niman	Respond to of 32384

Mudcat, I wasn't at the San Diego Field trip, so I can't say which receptors are in the "gobble up" category. The original alliance with SBH was to use the STAT technology to find small molecules that would replace injected hematopoietic growth factors. Epogen and Neupogen were at the top of the list and I believe that thrombopoietin was added. Recently, leptin was added. The SBH deal began in 1995 and I think that it was extended. Usually the precise terms of the milestone payments are not revealed before hand, and the milestones are frequently tied to clinical development, so they will probably not do much for LGND's bottom line until IND's are filed. LGND generally takes care of the preclinical aspects and their partners do the trials, marketing, and sales. The BioWorld report indicated that G-CSF was likely to be the lead candidate for the mimic technology. The table at home.att.net shows the arrow going about half way through the SELECTED column. When it gets all the way through, I suspect that an IND will be filed and LGND will get a milestone payment.